article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. View original article.

DEA 52
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DMT Therapy: Coming to a Clinic Near You?

Canna Law Blog

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” MDMA (Ecstasy) Nears FDA Approval for PTSD Treatment.

Therapy 90
article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). In 2018, the U.S.

article thumbnail

What is the Difference Between a Cannabis Recommendation and Cannabis Prescription

United Patients Group

Epidiolex, an FDA-approved medication containing CBD (cannabidiol), has been listed as Schedule 5 by the DEA since June 25th, 2019. The doctor who writes the prescription must be licensed and has to write it for a specific patient, as opposed to prescribing general instructions for treatment. Cannabis is a schedule 1 substance.

DEA 52
article thumbnail

Denver Cannabis Company to Expand Alzheimer’s Research

SpeedWeed

Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials. The license only allows MedPharm to conduct research on cannabis that was shifted through certain channels that have been approved by the government and DEA.

article thumbnail

CBD: Everything You Need to Know

CannaMD

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear. What can CBD do?

CBD 99